Tonabersat

Drug Profile

Tonabersat

Alternative Names: SB-220453; USL-260

Latest Information Update: 28 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer Proximagen
  • Class Antimigraines; Benzamides; Benzopyrans
  • Mechanism of Action Gap junction inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Epilepsy
  • Discontinued Migraine; Neuropathic pain

Most Recent Events

  • 29 Apr 2014 Phase I development of tonabersat in Epilepsy is ongoing
  • 14 Aug 2012 Proximagen has been acquired by Upsher-Smith
  • 14 Apr 2010 Proximagen exclusively sublicenses tonabersat to Upsher-Smith Laboratories for North America ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top